Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC010 in Combination With Chemotherapy for Advanced Lung Cancer
NCT07381829Phase 1Recruiting
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HC010 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Primary endpoint: Incidence of dose-limiting toxicities at 21 days. Started Oct 2025; status: recruiting.
02
Drugs
HC010
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07381829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381829.